cimzia (certolizumab pegol) recall — Ucb Biosciences Inc. (Class II)
Ucb Biosciences Inc. is recorded by the U.S. Food and Drug Administration (FDA) as recalling cimzia (certolizumab pegol) — a Class II recall, initiated 2026-05-08 and posted to the FDA enforcement report on 2026-05-27, under recall number D-0546-2026. Status Ongoing, with no termination date on the record. The reason the FDA record carries is, verbatim: “Lack of Assurance of Sterility”. From the product description, the form is kit, the package is described as 3 cartons and it is marked Rx only. 3 National Drug Code numbers are printed in the record: 50474-710-79, 50474-710-80 and 50474-710-81. Distribution is recorded as “US Nationwide” — Nationwide (US), with the recalling firm on record in GA, United States. It is the only recall number the FDA has filed under event ID 98915. 19 days separate the firm's initiation date from the FDA's report date on this record. Values are reproduced from the linked openFDA report; regulatory information, not medical advice.
Regulatory snapshot
| Recall number | D-0546-2026 |
|---|---|
| FDA event ID | 98915 |
| Classification | Class II (intermediate regulatory tier) |
| Status | Ongoing |
| Recalling firm | Ucb Biosciences Inc. |
| Recall initiated | 2026-05-08 |
| Reported by FDA | 2026-05-27 |
| Report lag | 19 days from initiation to report |
| Distribution | US Nationwide. — Nationwide (US) |
| Firm location on record | GA, United States |
| Product description (source) | cimzia (certolizumab pegol), 2x200mg/mL PREFILLED SYRINGES (2 single-dose), Rx ONLY, Manufactured by: UCB Inc., Smyrna, GA 30080, a) NDC 50474-710-79, b) Professional sample, NDC 50474-710-80; c) 3 cartons, STARTER KIT, NDC 50474-710-81. |
Reason reported by FDA
Lack of Assurance of Sterility
5 words from the enforcement report field reason_for_recall, reproduced without edit — the firm's own wording, not an assessment.
Product identifiers in this record
7 identifying values matched by exact pattern in the 32-word product description above; each is a literal substring of it.
| Product named | cimzia (certolizumab pegol) |
|---|---|
| Form | Kit |
| Package | 3 cartons |
| NDC | 50474-710-79 · 50474-710-80 · 50474-710-81 |
| Marketing category | Rx only |
| Manufactured by | UCB Inc., Smyrna |
Reported in the same month (2026-05)
48 enforcement reports carry a report date in 2026-05; these 8 are the Class II ones nearest this record.
| Recall record | Recall number | Recalling firm | FDA tier | Reported |
|---|---|---|---|---|
| Atomoxetine Capsules HCL, 10 mg | D-0538-2026 | Safecor Health, LLC | Class II | 2026-05-27 |
| Liraglutide Injection, 18 mg/3 mL | D-0541-2026 | Lupin Pharmaceuticals Inc. | Class II | 2026-05-27 |
| Gas-X, 125 mg | D-0542-2026 | Haleon US Holdings LLC | Class II | 2026-05-27 |
| Estradiol Gel, 0.1% | D-0543-2026 | Ani Pharmaceuticals, Inc. | Class II | 2026-05-27 |
| Erythromycin Tablets, 250 mg | D-0544-2026 | Zydus Pharmaceuticals (usa) Inc | Class II | 2026-05-27 |
| Erythromycin Tablets, 500 mg | D-0545-2026 | Zydus Pharmaceuticals (usa) Inc | Class II | 2026-05-27 |
| fentaNYL Citrate, 2,2500 mcg/50mL | D-0548-2026 | Integradose Compounding Services LLC | Class II | 2026-05-27 |
| Vitamin B-Complex, 799 mcg/5mL | D-0549-2026 | Safecor Health, LLC | Class II | 2026-05-27 |
Nearest Class II recalls by date
213 of 250 indexed records share the Class II tier; the 8 nearest to 2026-05-27 by report date are listed here.
| Recall record | Recall number | Recalling firm | Strength / form | Reported |
|---|---|---|---|---|
| Oasis Tears PF, 10mL | D-0525-2026 | Oasis Medical, Inc. | 10mL · Eye Drops | 2026-05-20 |
| Buprenorphine Hydrochloride, 0.3mg/mL | D-0527-2026 | Endo Usa, Inc. | 0.3mg/mL · Injection | 2026-05-20 |
| Ascend Laboratories, 25 mg | D-0547-2026 | Ascend Laboratories, LLC | 25 mg · Extended-Release Tablets | 2026-05-20 |
| DELFLEX, 1.5% | D-0512-2026 | Fresenius Medical Care Holdings, Inc. | 1.5% · Solution | 2026-05-13 |
| DELFLEX, 2.5% | D-0513-2026 | Fresenius Medical Care Holdings, Inc. | 2.5% · Solution | 2026-05-13 |
| Duloxetine Delayed-Release Capsules, 30 mg | D-0514-2026 | Ajanta Pharma Ltd. | 30 mg · Delayed-Release Capsules | 2026-05-13 |
| Duloxetine Delayed-Release Capsules, 60 mg | D-0515-2026 | Ajanta Pharma Ltd. | 60 mg · Delayed-Release Capsules | 2026-05-13 |
| Duloxetine Delayed-Release Capsules, 20 mg | D-0516-2026 | Ajanta Pharma Ltd. | 20 mg · Delayed-Release Capsules | 2026-05-13 |
Reading this record
Class II is the FDA's own severity tier for the recall action — 213 of the 250 indexed records carry it — and it describes the agency's assessment of the action, not a risk statement about any individual. Match a package against 50474-710-79, 50474-710-80 and 50474-710-81 at the FDA source to confirm it is covered.
Namespace context: the Class II index (213 records) and the recall hub (250 records, 118 FDA events); Ucb Biosciences Inc. (1 indexed records) aggregates this firm across datasets.
Coverage and limits of this record
This page reflects the openFDA enforcement report for D-0546-2026 as ingested on 2026-08-22, which can lag the live FDA record and omits detail held only in primary documents. It offers no clinical assessment, no advice about whether to use any product, and no substitute. For any health question consult a qualified healthcare professional.
Source & provenance
- Official source
- https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0546-2026%22
- Source dataset
- openFDA Drug Enforcement API
- Publication date
- 2026-05-27
- Ingested
- 2026-08-22
- Record hash
ab4329aee2e0d42d
Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.